New schemes

Body cavity fluids, identification of cells

Labquality is introducing a new scheme for Body cavity fluids, identification of cells. We are inviting a limited number of laboratories to participate in a pilot study of this new scheme free of charge. The scheme is intended for professionals involved in identifying digital images of microscopic findings of body cavity fluid cells.

Registration is open until 30 September 2026.

Joint infection multiplex, nucleic acid detection

Labquality is introducing a new scheme for Joint infection multiplex, nucleic acid detection. We are inviting a limited number of laboratories to participate in a pilot study of this new scheme free of charge.
The scheme is suitable for clinical laboratories and point-of-care testing sites.

Registration is open until 31 December 2026.

Tropical fever multiplex, nucleic acid detection

Labquality is introducing a new scheme for Tropical fever multiplex, nucleic acid detection. We are inviting a limited number of laboratories to participate in a pilot study of this new scheme free of charge.
The scheme is suitable for clinical laboratories and point-of-care testing sites.

Registration is open until 31 December 2026.

Alzheimer’s disease biomarkers

Labquality is planning to organise an EQA pilot study for Alzheimer’s disease biomarkers. In order to determine the level of interest for this program, we would appreciate your participation in our online survey.

Your response will provide valuable information for the development of our EQA programs.

There's still time to take part in the survey!

Extended phenotyping, blood group antigens

Labquality is introducing a new scheme for Extended phenotyping, blood group antigens. We are inviting a limited number of testing sites to participate in a pilot study of this new scheme free of charge.

Registration for this pilot study is closed.

NGS in clinical oncology

Preanalytics, extended specimen collection

Cryptosporidium/Giardia/Entamoeba, antigen detection

Candidozyma auris (ex Candida auris), nucleid acid detection

HCV RNA from capillary blood, POCT

Phosphatidyl ethanol in blood (PEth)

West Nile Virus, antibodies

HPV-related head and neck cancer control

Bacterial vaginosis and vaginitis multiplex, nucleic acid detection

Gram stain, vaginal fluid

Erythropoietin and Thrombopoietin

Immunosuppressants

Biochemical indicators of vitamin B12 deficiency (HoloTC, MMA, Homocysteine)

Norovirus, antigen detection

Helicobacter pylori, nucleic acid detection

Maternal serum screening

Mycoplasma genitalium, drug resistance multiplex, nucleic acid detection

Pipette control

Salivary Cortisol

Chemokine CXCL13

Interferon Gamma Release Assay (IGRA) for Mycobacterium tuberculosis

Faecal Elastase

Fungal infections, nucleic acid detection

Mycobacterium tuberculosis, drug resistance, nucleic acid detection

ACTH and Cortisol

HSV1&2/VZV/T.pallidum, nucleic acid detection

EQA for next-generation sequencing methods

We are developing external quality assessments for NGS methods in microbiology. If you are interested, please contact us!

EQA Product Catalogue

Our external quality assessment service program includes more than 250 quality assessment schemes, covering all specialities of laboratory medicine. Furthermore, the program includes an extensive selection of services designed for medical laboratories and point-of-care testing sites.

Integrated EQA Service

Our integrated EQA service is a completely new approach to external quality assessment. New programs integrate pre- and post-analytical EQA schemes into traditional analytical EQA, providing support according to the ISO 15189
standard requirements.

doctor-performing-medical-research-lab (1)

New EQA Schemes

We actively follow the development of laboratory medicine as we want to produce clinically relevant EQA schemes to serve clinical laboratories and point-of-care sites. We regularly launch new pilot studies and aim to expand our EQA portfolio by 5-10 new EQA schemes each year.

Local Partners Create Additional Value

We have EQA partners and distributors in more than 40 countries in Europe, South America, Southeast Asia, and the Middle East. Partner organisations sell and localise the EQA service in their territory. All partners have expertise in EQA and laboratory medicine.

Digital External Quality Assessment Programs

Our digital EQA product line provides an
advanced approach to external quality
assessment. Digital EQA programs or
virtual EQA programs use digital images,
videos, virtual microscopy technology, and
questionnaires as EQA samples.

Try the Demo